Isle of Man vs New Zealand: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Isle of Man
0.0%
in 2024
New Zealand
0.0%
in 2024
Isle of Man rank
167th
New Zealand rank
167th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Isle of Man
- New Zealand
How they compare
Isle of Man currently reports 0.0% against 0.0% in New Zealand, a difference of 0.0%.
Across all 10 years both countries report, New Zealand has been ahead every year.
Isle of Man ranks 167th and New Zealand ranks 167th of 246 countries.
Head to head by decade
| Decade | Isle of Man | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | — |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Isle of Man or New Zealand?
- Isle of Man, at 0.0% against 0.0% in New Zealand as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Isle of Man and New Zealand?
- 0.0%, with Isle of Man ahead.
- How many years of comparable data are there for Isle of Man and New Zealand?
- 10 years are reported by both, from 2015 to 2024.
- How do Isle of Man and New Zealand rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Isle of Man ranks 167th and New Zealand ranks 167th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.